Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
814 18 |
Ultima descărcare din IBN: 2021-12-31 10:07 |
Căutarea după subiecte similare conform CZU |
616.4-006.441-071 (3) |
Pathology of the lymphatic system, haemopoietic (haematopoietic) organs, endocrines (189) |
SM ISO690:2012 BURUIANA, Sanda. Aspecte clinice, hematologice şi imunohistochimice ale limfoamelor non-hodgkin limfocitare din limfocite mici. In: Revista ştiinţifico-practică ”Info-Med” , 2016, nr. 2(28-2), pp. 52-57. ISSN 1810-3936. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista ştiinţifico-practică ”Info-Med” | |||||||
Numărul 2(28-2) / 2016 / ISSN 1810-3936 | |||||||
|
|||||||
CZU: 616.4-006.441-071 | |||||||
Pag. 52-57 | |||||||
|
|||||||
Descarcă PDF | |||||||
Rezumat | |||||||
The clinical, hematologic and immunohistochemical aspects of non-Hodgkin’s lymphomas were studied in a group of 28 patients with the age range of 37-71 years old. The disease developed and prevailed in patients over 50 years old. The diagnosis was established by morphologic and immunohistochemical analyses, which proved to be CD19, CD20,CD5 and CD23 – pozitive. The primary tumor focus developed more frequently in the peripheral lymph nodes (50,0%) and in spleen (32,2%). During the generalization the bone marrow was frequently impaired (95%). In the majority of cases the IPI values were of highly negative risk and correlated with the survival rates, which constituted 87.3% within 3 years and 65.1% within 5 years. |
|||||||
Cuvinte-cheie non-Hodgkin’s lymphoma, immunohistochemistry, clinical, hematological |
|||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-48965</cfResPublId> <cfResPublDate>2016-11-22</cfResPublDate> <cfVol>28-2</cfVol> <cfIssue>2</cfIssue> <cfStartPage>52</cfStartPage> <cfISSN>1810-3936</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/48965</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Aspecte clinice, hematologice şi imunohistochimice ale limfoamelor non-hodgkin limfocitare din limfocite mici</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>non-Hodgkin’s lymphoma; immunohistochemistry; clinical; hematological</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'>The clinical, hematologic and immunohistochemical aspects of non-Hodgkin’s lymphomas were studied in a group of 28 patients with the age range of 37-71 years old. The disease developed and prevailed in patients over 50 years old. The diagnosis was established by morphologic and immunohistochemical analyses, which proved to be CD19, CD20,CD5 and CD23 – pozitive. The primary tumor focus developed more frequently in the peripheral lymph nodes (50,0%) and in spleen (32,2%). During the generalization the bone marrow was frequently impaired (95%). In the majority of cases the IPI values were of highly negative risk and correlated with the survival rates, which constituted 87.3% within 3 years and 65.1% within 5 years. </cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'>Были рассмотрены клинические, гематологические и иммуногистохимическое анализы 28 пациентов с неходжкинской лимфомой (НХЛ), малых лимфоцитов 37 лет до 71 лет. Болезнь была разработана преобладая у взрослых и у людей в возрасте старше 50 лет (89,3%). Диагноз был подтвержден и иммуногистохимические показатели CD19, CD20, CD5 и CD23 были положительными. Первичная опухоль чаще вырастает в лимфатических узлах (50,0%) и селезенки (32,2%). При постановке диагноза преобладали обобщенные стадии заболевания. В ходе обобщения часто была затронута кости (95%). IPI в большинстве случаев был высокий риск и отрицательно коррелирует с выживаемостью что намекает на то что в течение 3-х лет было 87,3%, а за 5 лет - 65,1%. </cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-11-22T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2016-11-22T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-17453</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-11-22T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-17453</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-17453-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-11-22T24:00:00</cfStartDate> <cfFamilyNames>Buruiana</cfFamilyNames> <cfFirstNames>Sanda</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>